| Description | 3M-011, a potent dual toll-like receptor TLR7/8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibits H3N2 influenza viral replication in the nasal cavity and exhibits strong antitumor activity[1][2][3]. |
| In vitro | 3M-011 (0-100 μg/mL; 24 hours; B16-F10 melanoma cells) treatment can decrease B16-F10 melanoma cell counts[1]. 3M-011 in humans activates both TLR7 and TLR8, whereas in mice, 3M011 activates only TLR7 and not TLR8[1]. The NF-κB reporter is stably integrated into HEK-293 cells that are subsequently transiently transfected with human or mouse TLR7 or TLR8. With all the TLRs tested, except mouse TLR8, stimulation with 3M-011 results in a dose-dependent induction of NF-κB-controlled luciferase activity. 3M-011 potentiates natural killer (NK) cells cytotoxicity[1]. |
| In vivo | 3M-011 (1 mg/kg; intravenous injection; every other day with six doses; female scid/NOD mice) treatment shows antitumor effects in scid/NOD mice bearing B16-F10 cells[1]. 3M-011 induces a dose-dependent increase in serum concentrations of both TNF-α and IFN-α/β[1]. Wild-type C57BL/6 mice are injected subcutaneously with different doses of 3M-011 (0.01 mg/kg, 0.1 mg/kg, 1 mg/kg, or 10 mg/kg). |
| molecular weight | 391.49 |
| Molecular formula | C18H25N5O3S |
| CAS | 642473-62-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Dumitru CD, et al. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother. 2009 Apr;58(4):575-87. 2. Hammerbeck DM, et al. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res. 2007 Jan;73(1):1-11. 3. Schölch S, et al. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget. 2015 Mar 10;6(7):4663-76. |